Drug Development

Pharmaceutical company obtains worldwide rights to recombinant human bFGF

Published in Gene Therapy Weekly, April 14th, 2005

Kaken Pharmaceutical Co., Ltd., Tokyo, Japan, and Chiron Corporation, Emeryville, California, have signed a license agreement on bFGF (FGF-2).

Through the license agreement with Chiron, Kaken has obtained the rights to develop, manufacture and sell bFGF products on a worldwide basis, having previously obtained rights to bFGF in Japan and other Asian countries.

Kaken has been conducting research and development on regenerative medicine using recombinant human bFGF for more than a decade, resulting in the success of the commercialization of a wound-healing drug Fiblast Spray in 2001. Kaken is also proceeding with clinical study on periodontitis and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry